Clinical applications of the interleukins: present and future

Clinical use of biologic agents, especially in the fields of hematology and oncology, is becoming increasingly common. Many agents, interferon-alpha, interferon-gamma, granulocyte and granulocyte-monocyte colony stimulating factors, erythropoietin, and interleukin-2 have already been approved for clinical use. Others are currently in clinical trials or will soon be available for administration to humans. This review summarizes the properties of interleukins 1 through 12, their derivation, activities, and approved or potential clinical uses.